dave297
01 Jun 2015
Re: Big Trades Someone must have bought those shares ,as MMs would not hold that many shares, & let s hope that NW has taken a "small " stake.He loves pharma s & what is not to love about SKP ?
dkok
01 Jun 2015
Big Trades Four big trades after hours for 1.5M shares? not even reported on iii?dkok
dkok
29 May 2015
Re: Odd UT Trade Actually, this pattern seems to be repeated on a number of shares on the UT today, with quite massive UT trades on a number being equivalent to 50% to 75% of the entire days trading, even on shares like VOD, Morrisons, Centrica, Sainaburys etc.Normally UT's are for smaller amounts, but is seems to be much bigger today across the board, unless it is a Friday thing that I just hadn't noticed before?dkok
dkok
29 May 2015
Odd UT Trade Very odd UT trade at the close of play of close to 600,000 shares at a price 3.5p below the closing sell price? haven't seen such a large UT trade at close which effectively was three times the size of the number of shares traded throughout the trading day.Anyone any thoughts on it?dkok
dkok
28 May 2015
Re: Pacira News Hi DaveWe can only hope so. To me the significance of the Pacira news is that they had actually filed for use for nerve block in total knee anthroplasty and thoracotomy, but it seems that the FDA have suggested it should be tested for use for all nerve block applications, which would be a huge increase in the potential market for Exparel. As it is the $56M 1st quarter '15 turnover that Exparel achieved relates to a market share of just 2% of what it possible for the procedures that it is currently approved for, so the potential here is massive.I am reasonably confident that Exparel will pass the $200M sales this year to trigger the next milestone payment for SKP, so not particularly worried by the subpoena, and it would seem that Pacira are starting to get the FDA on board with what they are trying to achieve, which will hopefully be positive.That Exparel is only a small part of SKP's turnover is testament to how far the company has come in the last couple of years to turn itself around. Now it is a case of them rolling out Fluti into the 14 markets that it is approved in but not yet marketed. There is still a lot of value to be unlocked in SKP yet, and they do need to start to do it, otherwise I could see GSK being a likely take out buyer, as it would fit with their plans to bolster their respiratory division which has suffered over the last couple of years.I wouldn't want to let go for anything less than £5/share though if they did come knocking.gltadkok
